Applied Therapeutics stock (APLT) was down 75% early Friday on news the FDA had declined to approve its drug govorestat, ...

Applied Therapeutics' New Drug Application for a rare metabolic disease was rejected by the Food and Drug Administration, ...

The pharma company's shares are getting crushed after regulators decline to green light a drug to treat a rare disease.

Applied Therapeutics said on Wednesday that the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic ...

Applied Therapeutics faces challenges after FDA rejection, but future opportunities exist. Learn why APLT stock could recover ...

Fintel reports that on November 29, 2024, RBC Capital downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from ...

FDA rejected Applied Therapeutics' Govorestat for galactosemia, citing NDA deficiencies. The company plans discussions for ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Baird analyst Brian Skorney lowered the firm’s price target on Applied Therapeutics (APLT) to $5 from $14 and keeps an Outperform rating on the ...

RBC Capital analyst Brian Abrahams downgraded Applied Therapeutics (APLT) to Sector Perform from Outperform with a price target of $4, down ...

In a statement, Applied Tx said it is reviewing the complete response letter (CRL) from the FDA and "plans to immediately ...

Applied Therapeutics' stock plummeted 75 percent after the Food and Drug Administration (FDA) rejected approving govorestat ...